# Safety of GSK Biologicals' Infanrix-IPV+HibTM Vaccine in Healthy Vietnamese Toddlers

> **NCT01577732** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 321 (actual)

## Conditions studied

- Acellular Pertussis
- Haemophilus Influenzae Type b
- Tetanus
- Poliomyelitis
- Diphtheria
- Diphtheria-Tetanus-aPertussis-Poliomyelitis-Haemophilus Influenzae Type b Vaccines

## Interventions

- **BIOLOGICAL:** Infanrix-IPV+Hib™

## Key facts

- **NCT ID:** NCT01577732
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-12-08
- **Primary completion:** 2013-04-09
- **Final completion:** 2013-04-09
- **Target enrollment:** 321 (ACTUAL)
- **Last updated:** 2020-01-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01577732

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01577732, "Safety of GSK Biologicals' Infanrix-IPV+HibTM Vaccine in Healthy Vietnamese Toddlers". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT01577732. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*